Chemotherapy for Advanced Transitional Cell Carcinoma
Author Information
Author(s): G.M. Jeffery, G.M. Mead
Primary Institution: CRC Wessex Regional Medical Oncology Unit
Hypothesis
Can combination chemotherapy improve survival in patients with advanced transitional cell carcinoma?
Conclusion
The study found that combination chemotherapy resulted in a 24% complete remission rate and a median survival of 7 months for patients with advanced transitional cell carcinoma.
Supporting Evidence
- 8 out of 33 patients with measurable disease achieved a complete remission.
- The median survival for patients achieving a complete remission was 13 months.
- Only three patients are still alive, with two being disease-free.
Takeaway
Doctors gave special medicine to 43 people with a type of cancer to see if it would help them live longer, and some got better.
Methodology
Patients received a combination chemotherapy regimen of cisplatin, methotrexate, and vinblastine over a maximum of six cycles.
Potential Biases
Patients were highly selected, which may not represent the general population with advanced TCC.
Limitations
The study included patients with varying degrees of health and some had non-measurable disease, which may affect the results.
Participant Demographics
The median age of participants was 65 years, with 35 males and 8 females.
Statistical Information
P-Value
0.0193
Statistical Significance
p=0.0193
Want to read the original?
Access the complete publication on the publisher's website